Last 12 months
Inside the activity.
0 purchase rows · 204 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 17 |
| Dec 2025 | 0 | 26 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 8 |
| Jun 2026 | 0 | 32 |
| Jul 2026 | 0 | 64 |
| Aug 2026 | 0 | 27 |
| Sep 2026 | 0 | 20 |
| Oct 2026 | 0 | 5 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 04, 2019 Filed Nov 6, 2019 18:50 UTC |
Chen Timothy Yung-ChengDirector
|
Exercise / conversionAmerican Depositary Shares | 4,000 | $41.01 | $164,040.00 |
DisclosureSEC source: 0001651308-19-000104 · wf-form4_157308420560017.xml · nonDerivative · entry 1 Chen Timothy Yung-Cheng · CIK 0001374068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:20 UTC |
Wu XiaobinPresident & GM China
|
SaleAmerican Depositary Shares | 1,000 | $180.00 | $180,000.00 |
DisclosureSEC source: 0001651308-19-000102 · wf-form4_157298880433664.xml · nonDerivative · entry 3 Wu Xiaobin · CIK 0001739452 · President & GM China 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:22 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 1,000 | $170.00 | $170,000.00 |
DisclosureSEC source: 0001651308-19-000103 · wf-form4_157298891097486.xml · nonDerivative · entry 4 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · security: Each American Depositary Share represents 13 Ordinary Shares. F4 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 00:15 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 82 | $129.40 | $10,610.56 |
DisclosureSEC source: 0001651308-19-000085 · wf-form4_156772890062328.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · shares: These shares were acquired under the BeiGene, Ltd. Second Amended and Restated Employee Share Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 03, 2019 Filed Sep 6, 2019 00:15 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 230 | $144.94 | $33,337.10 |
DisclosureSEC source: 0001651308-19-000085 · wf-form4_156772890062328.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax obligation in connection with the vesting of a restricted share award previously granted to the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.90 to $144.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ADSs, sold at each separate price. Read SEC document |
| September 03, 2019 Filed Sep 6, 2019 00:15 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 2,632 | $144.41 | $380,082.65 |
DisclosureSEC source: 0001651308-19-000085 · wf-form4_156772890062328.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax obligation in connection with the vesting of a restricted share award previously granted to the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.88 to $144.84, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ADSs, sold at each separate price. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 16:04 UTC |
Chen Timothy Yung-ChengDirector
|
Exercise / conversionShare Option (Right to Buy) · Derivative | 102,700 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001651308-19-000084 · wf-form4_156693627661112.xml · derivative · entry 7 Chen Timothy Yung-Cheng · CIK 0001374068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,926 Underlying: Ordinary Shares · 102,700 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F8 · derivative.exercise_date: These securities vest over a three-year period as follows: 1/3 of these securities become exercisable on each anniversary of February 8, 2016. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 16:04 UTC |
Chen Timothy Yung-ChengDirector
|
SaleAmerican Depositary Shares | 714 | $145.30 | $103,744.56 |
DisclosureSEC source: 0001651308-19-000084 · wf-form4_156693627661112.xml · nonDerivative · entry 6 Chen Timothy Yung-Cheng · CIK 0001374068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 16:04 UTC |
Chen Timothy Yung-ChengDirector
|
SaleAmerican Depositary Shares | 200 | $146.36 | $29,272.72 |
DisclosureSEC source: 0001651308-19-000084 · wf-form4_156693627661112.xml · nonDerivative · entry 5 Chen Timothy Yung-Cheng · CIK 0001374068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.3271 to $146.40, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 16:04 UTC |
Chen Timothy Yung-ChengDirector
|
SaleAmerican Depositary Shares | 6,700 | $145.08 | $972,007.86 |
DisclosureSEC source: 0001651308-19-000084 · wf-form4_156693627661112.xml · nonDerivative · entry 4 Chen Timothy Yung-Cheng · CIK 0001374068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 914 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.00 to $145.26, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 16:04 UTC |
Chen Timothy Yung-ChengDirector
|
SaleAmerican Depositary Shares | 286 | $143.01 | $40,900.17 |
DisclosureSEC source: 0001651308-19-000084 · wf-form4_156693627661112.xml · nonDerivative · entry 3 Chen Timothy Yung-Cheng · CIK 0001374068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,614 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.00 to $143.03, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 16:04 UTC |
Chen Timothy Yung-ChengDirector
|
Exercise / conversionAmerican Depositary Shares | 7,900 | $31.59 | $249,561.00 |
DisclosureSEC source: 0001651308-19-000084 · wf-form4_156693627661112.xml · nonDerivative · entry 2 Chen Timothy Yung-Cheng · CIK 0001374068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.82 to $143.969, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 16:04 UTC |
Chen Timothy Yung-ChengDirector
|
SaleAmerican Depositary Shares | 714 | $143.91 | $102,754.60 |
DisclosureSEC source: 0001651308-19-000084 · wf-form4_156693627661112.xml · nonDerivative · entry 1 Chen Timothy Yung-Cheng · CIK 0001374068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.82 to $143.969, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 20:47 UTC |
Huang JaneCMO, Hematology
|
Exercise / conversionShare Option (Right to Buy) · Derivative | 32,500 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001651308-19-000080 · wf-form4_156572920797757.xml · derivative · entry 7 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,465 Underlying: Ordinary Shares · 32,500 shares Expires 2027-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. F8 · derivative.exercise_date: The options vest over a four-year period as follows: 25% on the first anniversary of the date of grant, with the remaining shares vesting in 36 equal successive monthly installments on the last day of each month thereafter. Unvested options are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 20:47 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 500 | $136.91 | $68,454.00 |
DisclosureSEC source: 0001651308-19-000080 · wf-form4_156572920797757.xml · nonDerivative · entry 6 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.54 to $137.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 20:47 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 800 | $135.86 | $108,685.52 |
DisclosureSEC source: 0001651308-19-000080 · wf-form4_156572920797757.xml · nonDerivative · entry 5 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.39 to $136.24, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 20:47 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 400 | $134.34 | $53,736.00 |
DisclosureSEC source: 0001651308-19-000080 · wf-form4_156572920797757.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.96 to $134.72, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 20:47 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 800 | $132.47 | $105,979.20 |
DisclosureSEC source: 0001651308-19-000080 · wf-form4_156572920797757.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.19 to $132.69, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 20:47 UTC |
Huang JaneCMO, Hematology
|
Exercise / conversionAmerican Depositary Shares | 2,500 | $45.31 | $113,275.00 |
DisclosureSEC source: 0001651308-19-000080 · wf-form4_156572920797757.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:08 UTC |
Glazer Donald W.Director
|
OtherOrdinary Shares | 26,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-19-000081 · wf-form4_156581328904245.xml · nonDerivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,711,426 F3 · shares: The reporting person transferred these ordinary shares to his spouse pursuant to a divorce decree effective at a future date. The reporting person no longer reports as beneficially owned any securities owned by his spouse. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:08 UTC |
Glazer Donald W.Director
|
OtherAmerican Depositary Shares | 13,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-19-000081 · wf-form4_156581328904245.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · shares: The reporting person transferred these American Depositary Shares to his spouse pursuant to a divorce decree effective at a future date. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:04 UTC |
Huang JaneCMO, Hematology
|
Exercise / conversionShare Option (Right to Buy) · Derivative | 66,690 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001651308-19-000074 · wf-form4_156460344979901.xml · derivative · entry 7 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,044,775 Underlying: Ordinary Shares · 66,690 shares Expires 2026-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. F6 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:04 UTC |
Huang JaneCMO, Hematology
|
Exercise / conversionShare Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001651308-19-000074 · wf-form4_156460344979901.xml · derivative · entry 6 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882,965 Underlying: Ordinary Shares · 65,000 shares Expires 2027-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. F5 · derivative.exercise_date: The options vest over a four-year period as follows: 25% on the first anniversary of the date of grant, with the remaining shares vesting in 36 equal successive monthly installments on the last day of each month thereafter. Unvested options are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:04 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 7,630 | $135.10 | $1,030,821.39 |
DisclosureSEC source: 0001651308-19-000074 · wf-form4_156460344979901.xml · nonDerivative · entry 5 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.49, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:04 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 2,500 | $132.83 | $332,075.00 |
DisclosureSEC source: 0001651308-19-000074 · wf-form4_156460344979901.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,630 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:04 UTC |
Huang JaneCMO, Hematology
|
Exercise / conversionAmerican Depositary Shares | 5,130 | $29.49 | $151,283.70 |
DisclosureSEC source: 0001651308-19-000074 · wf-form4_156460344979901.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:04 UTC |
Huang JaneCMO, Hematology
|
Exercise / conversionAmerican Depositary Shares | 5,000 | $45.31 | $226,550.00 |
DisclosureSEC source: 0001651308-19-000074 · wf-form4_156460344979901.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 23:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 100 | $128.80 | $12,880.00 |
DisclosureSEC source: 0001651308-19-000073 · wf-form4_156271462402442.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax withholdings in connection with the vesting of restricted share unit awards previously granted to the Reporting Person. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 23:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 1,087 | $127.89 | $139,014.47 |
DisclosureSEC source: 0001651308-19-000073 · wf-form4_156271462402442.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F5 · security: Each American Depositary Share represents 13 Ordinary Shares F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax withholdings in connection with the vesting of restricted share unit awards previously granted to the Reporting Person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.80 to $128.19, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 23:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 719 | $127.19 | $91,450.98 |
DisclosureSEC source: 0001651308-19-000073 · wf-form4_156271462402442.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,187 F5 · security: Each American Depositary Share represents 13 Ordinary Shares F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax withholdings in connection with the vesting of restricted share unit awards previously granted to the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.72 to $127.65, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 23:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 1,200 | $125.59 | $150,710.04 |
DisclosureSEC source: 0001651308-19-000073 · wf-form4_156271462402442.xml · nonDerivative · entry 6 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,906 F5 · security: Each American Depositary Share represents 13 Ordinary Shares F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax withholdings in connection with the vesting of restricted share unit awards previously granted to the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.08 to $125.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 00:27 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 2,647 | $126.73 | $335,441.34 |
DisclosureSEC source: 0001651308-19-000070 · wf-form4_156202725072702.xml · nonDerivative · entry 5 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · security: Each American Depositary Share represents 13 Ordinary Shares. F4 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to fulfill a tax payment obligation in connection with the vesting of restricted share unit awards previously granted to the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.58 to $126.945, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 00:27 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 2,200 | $126.13 | $277,496.12 |
DisclosureSEC source: 0001651308-19-000070 · wf-form4_156202725072702.xml · nonDerivative · entry 4 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,647 F3 · security: Each American Depositary Share represents 13 Ordinary Shares. F4 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to fulfill a tax payment obligation in connection with the vesting of restricted share unit awards previously granted to the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.56 to $126.53, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| June 27, 2019 Filed Jul 2, 2019 00:30 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 3 | $126.33 | $378.99 |
DisclosureSEC source: 0001651308-19-000072 · wf-form4_156202740040079.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax withholdings in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. Read SEC document |
| June 27, 2019 Filed Jul 2, 2019 00:30 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 427 | $124.50 | $53,162.95 |
DisclosureSEC source: 0001651308-19-000072 · wf-form4_156202740040079.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax withholdings in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. Read SEC document |
| June 27, 2019 Filed Jul 2, 2019 00:28 UTC |
Liang HowardCFO & Chief Strategy Officer
|
SaleOrdinary Shares | 5,876 | $9.47 | $55,652.77 |
DisclosureSEC source: 0001651308-19-000071 · wf-form4_156202731319451.xml · nonDerivative · entry 1 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,317 F1 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price per ordinary share. One ordinary share equals 1/13 American Depositary Share. These shares were sold in multiple transactions at prices ranging from $9.188 to $9.5269, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 14:41 UTC |
Yi QingqingDirector
|
OtherOrdinary Shares | 9,282 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-19-002801 · ownership.xml · nonDerivative · entry 1 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents a transfer of shares by Qingqing Yi ("Mr. Yi") to certain funds managed by his employer and for whose benefit he was holding the shares. Mr. Yi expressly disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. F2 · shares: The 9,290 restricted share units ("RSUs") previously reported by Mr. Yi on June 8, 2018 were revised to 9,282 RSUs to be divisible by 13, as each of the Issuer's American Depositary Shares represents 13 Ordinary Shares. The Share Options previously reported by Mr. Yi on the same date were revised to 17,433 Share Options for the same reason. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:28 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
OtherOrdinary shares | 43,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-000596 · doc4_6149.xml · nonDerivative · entry 8 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,109 F2 · kind: Represents Ordinary Shares or ADS, as applicable, distributed by 667, L.P. ("667" and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667. F2 · price: Represents Ordinary Shares or ADS, as applicable, distributed by 667, L.P. ("667" and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667. F10 · balance_after: Ordinary Shares held directly by Julian C. Baker including 43,109 Ordinary Shares received from the in-kind pro rata distributions without consideration reported above. F15 · balance_after: Ordinary shares are convertible into ADS on a 13:1 basis. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:28 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
OtherOrdinary shares | 43,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-000596 · doc4_6149.xml · nonDerivative · entry 7 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,109 F2 · kind: Represents Ordinary Shares or ADS, as applicable, distributed by 667, L.P. ("667" and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667. F2 · price: Represents Ordinary Shares or ADS, as applicable, distributed by 667, L.P. ("667" and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667. F9 · balance_after: Ordinary Shares held directly by Felix J. Baker including 43,109 Ordinary Shares received from the in-kind pro rata distributions without consideration reported above. F15 · balance_after: Ordinary shares are convertible into ADS on a 13:1 basis. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:28 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
OtherOrdinary shares | 582,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-000596 · doc4_6149.xml · nonDerivative · entry 6 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 18,591 F2 · kind: Represents Ordinary Shares or ADS, as applicable, distributed by 667, L.P. ("667" and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667. F2 · price: Represents Ordinary Shares or ADS, as applicable, distributed by 667, L.P. ("667" and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667. F3 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. F6 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F7 · ownership.nature: Includes beneficial ownership of 9,290 restricted share units ("RSU's") convertible solely into Ordinary Shares of the Issuer each previously granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser in their capacity as directors of the Issuer. Michael Goller and Ranjeev Krishana serve on the Board (defined below) as representatives of the Funds. F8 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the RSU's and non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options") received as a result of their service on the Board. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the RSU's and Share Options (i.e. no direct pecuniary interest). F15 · ownership.nature: Ordinary shares are convertible into ADS on a 13:1 basis. F16 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:28 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
OtherAmerican Depositary Shares | 13,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-000596 · doc4_6149.xml · nonDerivative · entry 4 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,618 F2 · kind: Represents Ordinary Shares or ADS, as applicable, distributed by 667, L.P. ("667" and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667. F2 · price: Represents Ordinary Shares or ADS, as applicable, distributed by 667, L.P. ("667" and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667. F5 · balance_after: ADS held directly by Felix J. Baker including 13,516 ADS received from the in-kind pro rata distributions without consideration reported above. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:28 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
OtherAmerican Depositary Shares | 13,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-000596 · doc4_6149.xml · nonDerivative · entry 3 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,618 F2 · kind: Represents Ordinary Shares or ADS, as applicable, distributed by 667, L.P. ("667" and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667. F2 · price: Represents Ordinary Shares or ADS, as applicable, distributed by 667, L.P. ("667" and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667. F4 · balance_after: ADS held directly by Julian C. Baker including 13,516 ADS received from the in-kind pro rata distributions without consideration reported above. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:28 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
OtherAmerican Depositary Shares | 182,539 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-000596 · doc4_6149.xml · nonDerivative · entry 2 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,028,034 F2 · kind: Represents Ordinary Shares or ADS, as applicable, distributed by 667, L.P. ("667" and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667. F2 · price: Represents Ordinary Shares or ADS, as applicable, distributed by 667, L.P. ("667" and together with Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667. F3 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. F6 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F16 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 22:28 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantShares Option (Right to Buy) · Derivative | 129,220 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001638599-19-000596 · doc4_6149.xml · derivative · entry 9 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 129,220 Underlying: Ordinary Shares · 129,220 shares Expires 2029-06-04 F11 · derivative.exercise_date: 64,610 Share Options convertible solely into Ordinary Shares of the Issuer each were granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser in their capacity as directors of the Issuer. The Share Options with a strike price of $9.23 vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting provided, however, that all vesting shall cease if Michael Goller or Ranjeev Krishana resigns from the Board of Directors (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. The Share Options expire on June 4, 2029. Michael Goller and Ranjeev Krishana serve on the Board of the Issuer as representatives of the Funds. Unvested Share Options are subject to accelerated vesting upon a change in control or certain termination events. F8 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the RSU's and non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options") received as a result of their service on the Board. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the RSU's and Share Options (i.e. no direct pecuniary interest). F11 · ownership.nature: 64,610 Share Options convertible solely into Ordinary Shares of the Issuer each were granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser in their capacity as directors of the Issuer. The Share Options with a strike price of $9.23 vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting provided, however, that all vesting shall cease if Michael Goller or Ranjeev Krishana resigns from the Board of Directors (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. The Share Options expire on June 4, 2029. Michael Goller and Ranjeev Krishana serve on the Board of the Issuer as representatives of the Funds. Unvested Share Options are subject to accelerated vesting upon a change in control or certain termination events. F12 · ownership.nature: The disclosure of the grant Share Options reported on this form is a grant of 64,610 Share Options to each director referenced above. The 64,610 Share Options are reported for each of the Funds as each has an indirect pecuniary interest. F13 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Share Options to purchase Ordinary Shares of the Issuer beneficially owned by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. F14 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Share Options to purchase Ordinary Shares of the Issuer beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP),LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. F15 · ownership.nature: Ordinary shares are convertible into ADS on a 13:1 basis. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:05 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
GrantShare Option (Right to Buy) · Derivative | 2,193,282 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001651308-19-000053 · wf-form4_155993789923478.xml · derivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,193,282 Underlying: Ordinary Shares · 2,193,282 shares Expires 2029-06-04 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · balance_after: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:18 UTC |
Huang JaneCMO, Hematology
|
GrantShare Option (Right to Buy) · Derivative | 462,579 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001651308-19-000061 · wf-form4_155993868234485.xml · derivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,579 Underlying: Ordinary Shares · 462,579 shares Expires 2029-06-04 F2 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. F2 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · balance_after: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:18 UTC |
Huang JaneCMO, Hematology
|
GrantOrdinary Shares | 62,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-19-000061 · wf-form4_155993868234485.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,463 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 5, 2019, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 16:14 UTC |
Chen Timothy Yung-ChengDirector
|
GrantShare Option (Right to Buy) · Derivative | 64,610 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001651308-19-000058 · wf-form4_155993846069722.xml · derivative · entry 1 Chen Timothy Yung-Cheng · CIK 0001374068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,610 Underlying: Ordinary Shares · 64,610 shares Expires 2029-06-04 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F1 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:07 UTC |
Malley ThomasDirector
|
GrantShare Option (Right to Buy) · Derivative | 64,610 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001651308-19-000054 · wf-form4_155993800860144.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,610 Underlying: Ordinary Shares · 64,610 shares Expires 2029-06-04 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F1 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 16:11 UTC |
su Jingshyh SDirector
|
GrantShare Option (Right to Buy) · Derivative | 64,610 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001651308-19-000056 · wf-form4_155993828045293.xml · derivative · entry 1 su Jingshyh S · CIK 0001315720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,610 Underlying: Ordinary Shares · 64,610 shares Expires 2029-06-04 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F1 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F1 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.